← All tickers

Is ANVS Worth Buying in 2026?

Annovis Bio, Inc.

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-05-24

Here’s whether Annovis Bio, Inc. (ANVS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: above the 50-day MA (medium-term momentum positive); RSI 48 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-3.82% over 10 days); 3-month momentum negative (-16.8%). Currently 59.5% off its 52-week high. Score: -2/7.

Ready to act on this? 📈 Trade on Webull

ANVS is trading below its 200-day MA ($2.63) — a key warning sign the longer-term trend is under pressure. An RSI of 47.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +7.2% compares to +27.9% for SPY (trailed the market by 20.7%). The current 59.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $10,721 today
vs. S&P 500 (SPY) — same period trailed market by 20.7%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✗Above 200-day MA ($2.63)
✓Above 50-day MA ($2.13)
✓RSI(14) neutral zone (30–70) — currently 47.8
✓Positive return (+7.2%)
!Within 10% of period high (−59.5%)
Period Range $2.23
$1.54 $5.50
RSI (14) 47.8
0 · OversoldOverbought · 100

Key Metrics

Price$2.23
Period Return+7.2%
Period High$5.50
Period Low$1.54
Drawdown−59.5%
MA-50$2.13
MA-200$2.63
RSI (14)47.8
Avg Volume (30d)1.2M
vs. SPYtrailed by 20.7%
Return Rank#656 of 1236

Trade ANVS

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers